All news

Novonesis eyes gut health supplements for GLP-1 users

CNBC · RSS · · AI-summarised by FinFlash

Novonesis is exploring whether gut health supplements could benefit patients taking GLP-1 weight-loss drugs, opening a potentially lucrative new market. The Danish bioscience group is testing a product angle tied to the fast-growing class of obesity and diabetes treatments. For investors, the move signals a possible new revenue stream adjacent to the GLP-1 boom.

Read original source

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.